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Objective: To investigate whether a new blood collection device stabilizes cell-free RNA (cfRNA) in blood
post-phlebotomy when compared to collection using K3EDTA tubes.
Design and methods: Blood samples were drawn from healthy donors into K3EDTA tubes and Cell-Free
RNA BCTs (BCTs) and stored at room temperature (20–25 °C). At speciﬁed time points (days 0–3), plasma
was separated and cfRNA was extracted. Reverse transcription real-time PCR was used to quantify mRNA
for c-fos, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and for 18S rRNA.
Results: Blood drawn into K3EDTA tubes showed a steady increase in RNA concentration over 3 days of ex
vivo incubation. Blood drawn into BCTs showed no statistically signiﬁcant change in RNA copy number
except for GAPDH on day 3.Conclusions: The novel chemical cocktail contained in the new device allows for the stabilization of
cfRNA in blood samples at room temperature, which potentially enhances the clinical utility of cfRNA.© 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.Introduction
Since the discovery of cell-free nucleic acids (cfna) in peripheral
blood [1], elevated cfna levels have been associated with certain dis-
ease conditions [2]. These ﬁndings have implicated cfna as diagnostic
and prognostic indicators for disease pathology. The potential clinical
use of cell-free RNA (cfRNA) was ﬁrst demonstrated in patients with
nasopharyngeal carcinoma [3] and malignant melanoma [4]. Later,
tumor-associated mRNAs for telomerase components were detected
in serum or plasma of patients with breast cancer [5], colorectal
cancer, follicular lymphoma [6], and hepatocellular carcinoma [7].
Cytokeratin 19 and mammaglobin mRNAs, present in the plasma of
breast cancer patients, were associatedwith poor prognosis [8]. Similar-
ly, plasma samples from patients with advanced stage colorectal cancer
contained detectable levels of cytokeratin 19 and carcinoembryonic
antigen mRNA [9]. Wong et al. [10] has proposed that β-catenin
mRNA might be used as a biomarker because of its presence in the
plasma of patients with colorectal carcinoma and adenoma.
The occurrence of fetal cfRNA in maternal blood was initially
reported in 2000 by Poon et al. [11] and subsequently other fetal/
placental-speciﬁc cfRNAs were also found including human placental
lactogen, the β-subunit of human chorionic gonadotropin, and
corticotrophin-releasing hormone [12]. Additionally, elevated mRNA
levels of corticotrophin-releasing hormone were found in women
with pre-eclampsia [13]. Such discoveries provide opportunities for
the development of non-invasive diagnostic and prognostic testsStreet, Omaha, NE 68128, USA.
do).
mists. Published by Elsevier Inc. Opbased on cfRNA. However, many pre-analytical variables remain
that might impact the clinical utility of cfRNA that have yet to be
studied in detail. The stability of cfRNA can be affected substantially
during blood processing, shipping, and storage. It has been reported
that cell-free β-actin mRNA levels in plasma decrease with time
after blood collection likely due to in vitro RNA degradation [14].
Another study showed that cfRNA levels for both glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) and beta-2-microglobulin
increase with time after blood draw [15]. This increase in background
RNA (bRNA) levels can hamper the detection of low abundance cfRNA
targets. In order to use plasma cfRNA in clinically relevant ways,
post-phlebotomy changes in cfRNA and bRNA must be prevented.
Taken together, there is a clear need for the stabilization of cfRNA in
blood as well as maintenance of cfRNA integrity during sample
manipulation. The aim of this study was to determine if a new
blood collection device (Cell-Free RNA BCT) stabilizes cfRNA and
prevents bRNA release.
Materials and methods
Recruitment of blood donors
Blood donors were recruited with informed consent from Streck
Inc., Omaha, NE. Donors were both male and female, and presumed
to be healthy.
Blood collection
Donor samples were drawn, using venipuncture, into two differ-
ent blood collection tubes: a K3EDTA blood collection tube (BDen access under CC BY-NC-ND license.
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RNA™ BCT (BCT) (Streck, Inc. Omaha, NE). BCTs contain a novel
stabilizing chemical cocktail as well as K3EDTA as an anti-coagulant.
Blood was mixed well immediately after the draw by inverting
tubes 10 times each. BCTs and K3EDTA draws were kept at room
(20–25 °C) or refrigerated temperatures (2–8 °C) where indicated
(note: the BCT instructions for use advise blood storage at 18–25 °C).
Sample processing
Plasma was separated from blood 2 h post collection (day 0) or
after 1, 2, or 3 days as noted. To separate plasma, sample tubes
were centrifuged at 300×g for 20 min at room temperature. The
upper plasma layer was removed without disturbing the buffy coat
and transferred to a new tube that was then centrifuged at 5000×g
for 10 min to assure cell-free plasma. The clariﬁed plasma was then
transferred to a new tube for storage at −80 °C pending RNA
extraction.
Cell-free RNA isolation from plasma
The cfRNA was extracted and puriﬁed from plasma using the
QIAamp® Circulating Nucleic Acid Kit (Qiagen, Santa Clarita, CA).
The manufacturer's recommended protocol was modiﬁed slightly by
increasing the duration of the Proteinase K treatment at 60 °C from
30 min to 1 h (subsequent experiments showed no difference in
RNA ampliﬁcation between samples digested for 30 min or the mod-
iﬁed 1 h [data not shown]). An on-column DNase treatment step was
included to remove DNA and cfRNA was eluted in 30 μL nuclease-free
water that was passed over the column twice.
Detection of RNase activity in plasma obtained from K3EDTA and Cell-
Free RNA BCT tubes
In preliminary experiments, plasma was separated from blood on
day 0 from K3EDTA tubes as described above and portion of plasma
was treated with BCT chemical cocktail while another was left
untreated. In a separate experiment, blood was drawn into BCT and
K3EDTA tubes, stored as whole blood at room temperature and plasma
was separated as described above. RNase activity wasmeasured using a
commercially available RNase activity detection kit, RNaseAlert® Lab
Test Kit (Life Technologies, Grand Island, NY) and the manufacturer's
recommended protocol was followed.
Effect of chemical cocktail on cfRNA extraction and ampliﬁcation
Blood from seven donors was drawn into K3EDTA tubes, individual
donors were pooled, plasma was separated, and aliquoted. Half of the
aliquots were mixed with the chemical cocktail present in BCTs while
the other half remained untreated. All samples were stored at room
temperature. Total cfRNAwas extracted from untreated and chemically
treated plasma using lysis buffer without carrier RNA on days 0 and 3
and then total RNA was quantiﬁed using a NanoDrop spectrophotome-
ter. For the experiments conducted to investigate the stability of
β-actin and c-fos mRNAs, the same nucleic acid isolation kit was used
without any modiﬁcation to manufacturer's recommended protocol.
Samples extracted with carrier RNA were analyzed using primers and
probes for β-actin and c-fos to quantify β-actin and c-fos mRNA copy
numbers as discussed below.
RT-qPCR
All primers were purchased from Integrated DNA Technologies (IDT)
(Coralville, IA). All probes for TaqMan® assays were purchased from
Applied Biosystems (Foster City, CA), except for β-actin, which was pur-
chased from IDT. Primers and probe for the quantiﬁcation by RT-qPCRof c-fos mRNA were prepared as previously described [16]. Primers and
probe for RT-qPCR of GAPDHmRNAwere also prepared as previously de-
scribed [17]. The primers and probe used to quantify 18S rRNA by
RT-qPCR were: 5′ (forward) primer was 5′-CGAATGTCTGCCCTATCAAC-
3′; the 3′ (reverse) primer was 5′-GTTTCTCAGGCCCCTCTCC-3′; the
probe was 5′-FAM GTAGGCACGGCGACTACCATCGAAA TAMRA-3′. To
perform RT-qPCR, a TaqMan® RNA-to-CT™ 1-Step Kit was purchased
from Applied Biosystems (Foster City, CA). Plasmid DNA constructs
were prepared by cloning a DNA fragment into Zero Blunt TOPO
(Invitrogen, Carlsbad, CA); with each construct containing a single copy
of human c-fos, GAPDH, or 18S rRNA. The resulting amplicons had lengths
of 67 bp, 75 bp, and 105 bp, respectively. These plasmid constructs were
used to plot the standard curves except for β-actin, which required a syn-
thetic oligonucleotide (Ultramer™ Oligo) that was purchased from IDT.
The primers and probe for β-actin were: 5′ (forward) primer; 5′-GAGAC
CTTCAACACCCCAG-3′; 3′ (reverse) primer; 5′-ATCACGATGCCAGTGGT
AC-3′, probe; 6-FAM-CCATGTACGTTGCTATCCAGGCTGT-3′TAMRA. This
produced an 86 bp amplicon.
Blood cell stability
Blood from 8 donors was drawn into BCT and K3EDTA tubes and
plasma separated as described above. Evaluation of hemolysis was
done by measuring plasma hemoglobin as previously described,
using a Helios Beta UV–vis spectrophotometer (Thermo Spectronic,
Rochester, NY) [18]. Whole Blood samples were evaluated for cell sta-
bility using an Abbott CELL-DYN® Sapphire® hematology analyzer
(Santa Clara, CA).
Statistical analysis
Statistical analysis was carried out using the online free calculations
version of GraphPad. (http://www.graphpad.com/quickcalcs/index.
cfm). Paired Student's t-test was used and pb0.05 was considered
statistically signiﬁcant. Fold change calculations were determined as
previously described [19].
Results
Effect of stabilization chemical cocktail on RNase activity
We tested if the proprietary chemicals present in BCTs inhibited
RNase activity in blood, which would prevent the destruction of
cfRNA during room temperature storage (Fig. 1A). The RNase activity
of 5 μL of RNase A, as supplied with the kit, was used as a positive
control. Addition of the chemical cocktail to 5 μL of RNase A, at the
same concentration present in a 10 mL blood draw, resulted in a sig-
niﬁcant inhibition of RNase A activity (pb0.001). The RNase activity
in 2 μL of plasma from blood drawn into K3EDTA tubes showed an
RNase activity comparable to the positive control. However, 2 μL of
plasma from blood drawn into a BCT showed signiﬁcant inhibition
of RNase A activity (pb0.001).
Fig. 1B shows the effect of BCT chemical cocktail on RNase activity
when blood was stored at room temperature over a 3 day period.
Compared to plasma from blood stored in K3EDTA tubes, BCT plasma
showed an almost complete inhibition of RNase activity at all three
time points (pb0.001 for all three points).
Effect of chemical cocktail on cfRNA extraction and ampliﬁcation
We investigated whether the chemicals present in BCTs degrade
or chemically modify cfRNA. Chemically treated and untreated
plasmas were stored at room temperature over 3 days. Total cfRNA
concentration measurement by spectrophotometry on day 0 and
day 3 showed no statistically signiﬁcant difference between the two
treatment groups (Fig. 2A). Fig. 2B and C show the effects of the
Fig. 2. Effect of chemical cocktail in BCTs on extraction, puriﬁcation, and detection of
RNA. For all experiments in Fig. 2, blood from seven donors was drawn into K3EDTA
tubes, the plasma was separated by centrifugation, and plasma was pooled before
being aliquoted. To one group of plasma (black bars), chemicals were added that
were equal to the concentration of BCT chemical cocktail present in a normal blood
draw. The other group (white bars) was untreated and used as a control. Plasma was
stored at room temperature. (A) To test the effects of the chemical cocktail on RNA ex-
traction, plasma aliquots were removed from whole blood at days 0 and 3. Total RNA
was extracted without carrier RNA and quantiﬁed using a NanoDrop spectrophotome-
ter. Error bars indicates SD, (n=7). The effect of the chemical cocktail was also checked
by detection of (B) β-actin and (C) c-fos mRNA by RT-qPCR. Aliquots of plasma were
removed at days 0, 1, 2, and 3. Total RNAwas extracted and β-actin and c-fos mRNA con-
centrations (copies/mL plasma) were determined by RT-qPCR. Throughout the three day
storage, no signiﬁcant decrease in β-actin mRNA was observed for untreated and
chemically treated samples. Untreated samples showed a steady decrease in c-fos
Fig. 1. RNase activity inhibition by BCT chemical cocktail. (A) Five microliters of RNase
A (RNase Only) served as a positive control (RNaseAlert® Lab Test Kit). The chemical
cocktail present in BCTs was then added to the reaction mixture of the positive control,
which signiﬁcantly reduced RNAse activity (RNase+BCT Cocktail). Plasma samples
(2 μL) obtained from K3EDTA (EDTA Plasma) and BCT (BCT Plasma) blood draws
were tested for RNase activity following the manufacturer's recommended protocol.
Plasma from blood drawn into BCT showed a signiﬁcant reduction in RNAse activity
compared to plasma from blood drawn into K3EDTA. Error bars indicate SD, (n=6),
**pb0.001. (B) Whole blood was drawn into K3EDTA (white bars) and BCTs (black
bars) and stored at room temperature for 3 days to measure RNase activity over
time. Aliquots of blood were removed on days 0, 1, and 3, plasma was separated,
and 2 μL of the plasma was used to measure RNase activity. Error bars indicate SD,
(n=8), **pb0.001.
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tively, using RT-qPCR to determine mRNA copy number. Fig. 2B
illustrates that β-actin mRNA is stable in both treated and untreated
plasma over a 3 day period at room temperature and showed no sta-
tistically signiﬁcant decrease in β-actin ampliﬁcation. However, c-fos
mRNA was considerably more labile under the same conditions
(Fig. 2C). Untreated plasma c-fos mRNA showed a statistically signif-
icant decrease on days 1, 2, and 3 as compared to the initial time
point. There was no statistically signiﬁcant decrease in chemically
treated plasma c-fos mRNA after 1 day of storage, and a small but sta-
tistically signiﬁcant decrease was observed on days 2 (p=0.0082)
and 3 (p=0.0062) as compared to day 0.mRNA concentration over time in as compared to day 0 value. c-fos mRNA concentration
in chemically treated samples showed no signiﬁcant change up to day one, however
there was moderate but statistically signiﬁcant decline on days 2 and 3 (day 0 versus
day 2; pb0.001; day 0 versus day 3; pb0.001). Error bars indicate SD, (n=7).Stabilization of cfRNA
We evaluated the effects of BCTs versus K3EDTA on the stabilization
of cfRNA levels in whole blood draws stored over 3 days at room
temperature. RT-qPCR was run to quantify cfRNA using gene-speciﬁc
assays for GAPDH, c-fos, and 18S RNA. Fig. 3A illustrates the changesobserved in GAPDH mRNA levels over the three day storage period.
When blood was drawn and stored in K3EDTA tubes, statistically signif-
icant changes occurred over the storage period (p=0.0017, 0.0003,
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measurement of GAPDH copy number did not show statistically
signiﬁcant changes after 2 days of storage, as compared to day 0 (p=
0.2753 and 0.3662, respectively) but day 3 did show a statistically
signiﬁcant difference when compared to the initial data point (p=
0.0012). However, when fold change calculations were performed,
the increase in GAPDH on day 3 for BCT was only 1.5 fold versus an
increase of 22 fold in K3EDTA.
Fig. 3B shows the changes in c-fos levels over a three day storage
period. When blood was drawn into K3EDTA and stored, there was a
steady increase in c-fos copy number detected over the three day
experiment as compared to the day 0 copy number (p=0.1168,
0.0526, and b0.0001, respectively), which was a statistically signiﬁcant
increase on day 3. The BCT draws, however, showed no statisticallyFig. 3. Effect of ex vivo incubation of blood samples on plasma RNA concentration in K3EDTA
stored at room temperature. Aliquots were removed on days 0, 1, 2, and 3, plasma RNA w
RT-qPCR. Over time, statistically signiﬁcant changes in the copy numbers of GAPDH, c-fos,
number changes in blood drawn into BCTs except for GAPDH day 3 time point where th
boxes indicates the median value. The limits of the boxes represent the 75th and 25th
The dots indicate maximum and minimum values. *pb0.05, **pb0.01, ***p≤0.001 (GAPDHsigniﬁcant change over the course of the study (p=0.3289, 0.5448,
and 0.4531, respectively).
Fig. 3C shows the results for 18S rRNA over the three day storage
period. When compared to the day 0 copy number, 18S cfRNA from
blood drawn into BCTs show no statistically signiﬁcant increases on
days 1, 2, or 3 (p=0.4400, 0.5672, and 0.8719, respectively). In con-
trast, the samples from blood drawn into K3EDTA show a statistically
signiﬁcant increase in 18S rRNA copy number over the course of the
same storage period (p=0.0002, 0.0027, and 0.0008, respectively).
Finally, when the cfRNA stabilization studies were repeated with
refrigerated instead of room temperature storage, the changes observed
were statistically similar. This indicated that refrigeration of blood sam-
ples drawn into K3EDTA does not sufﬁciently mitigate the changes from
bRNA leakage or cfRNA degradation (data not shown).tubes or BCTs. Blood from ﬁfteen donors were drawn into K3EDTA tubes and BCTs and
as isolated, and RNA for (A) GAPDH, (B) c-fos, and (C) 18S rRNA were quantiﬁed by
and 18S rRNA were observed in K3EDTA samples while there were no signiﬁcant copy
ere was a slight (1.4-fold) but statistically signiﬁcant increase. The line inside of the
percentiles. The upper and lower error bars indicate the 10th and 90th percentiles.
n=15, c-fos n=14, and 18S n=13).
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We evaluated hemolysis by measuring plasma hemoglobin
concentration. Mean hemoglobin concentrations in K3EDTA tubes on
days 0, 1, and 3 were 0.029, 0.022, and 0.029 g/L, respectively, while
BCT had 0.034, 0.021, and 0.023 g/L on days 0, 1 and 3, respectively.
There was neither signiﬁcant hemolysis nor statistical change in
plasma hemoglobin concentration observed during the three day
room temperature storage for both K3EDTA tubes and BCT, suggesting
that the integrity of red cells was maintained. Analysis of whole
blood samples on the Abbott CELL-DYN Sapphire hematology analyzer
conﬁrmed this ﬁnding. Both red cell counts and histograms remained
stable through the three day testing period. However, blood drawn in
K3EDTA tubes started to show diffused white cell scattergrams after
1 day of room temperature storage, which indicates cell damage and
degradation. Conversely, scattergrams of white cells in BCT indicated
that the cells were well preserved and stable for up to 3 days (data
not shown).
Discussion
Circulating cfRNA in blood has potential value in non-invasive di-
agnosis and prognosis. Two major factors appear to limit the effective
use of cfRNA in clinical testing: (1) the masking of true cfRNA targets
due to bRNA release and (2) the degradation of cfRNA due to plasma
nucleases or sample handling. The high concentration of RNases in
plasma has been established previously [20]. With such high levels
of RNase activity in plasma, it is surprising that cfRNA can be detected.
Some studies [21–23] have proposed that cfRNA might be contained
in apoptotic bodies, whose sealed membranes provide cfRNA protec-
tion from RNase degradation. Others [24] suggest that plasma cfRNA
exists in two forms, contending that a substantial proportion exists
as a particle associated species that is protected from degradation
while the remainder is present in a non-particle associated form
that is labile and susceptible to degradation.
Holford et al. [14] have found that β-actin cfRNA concentrations in
plasma decrease over time when stored at 4 °C, which they attributed
to RNase-based degradation. Therefore, it is important to rapidly
inhibit plasma RNases in blood samples to assure that cfRNA integrity
is preserved. As shown in Fig. 1, if chemicals present in BCTs were
mixed directly with RNase, the enzyme activity was inhibited. We
have further shown that plasma from blood drawn into the new
device has little remaining RNase activity but plasma from blood
drawn into K3EDTA showed no decrease in RNase activity. This
suggests that one of the two main limiting factors for the clinical
utilization of cfRNA can be mitigated by using BCTs through the
rapid inactivation of plasma RNases.
We wanted to determine if the chemical cocktail present in BCT
caused a decrease in RNA isolation or ampliﬁcation (Fig. 2). To this
end, we compared cfRNA yields isolated from untreated plasma to
yields from the same plasma after treatment with the collection
device's chemical cocktail (Fig. 2A). When compared to day 0, no statis-
tically signiﬁcant decreases in total cfRNA yields were observed
between the treated group and the untreated group over 3 days of
storage at room temperature. This indicates that chemicals present in
the BCTs had no adverse effect on cfRNA isolation from blood plasma.
We investigated the effect of chemical cocktail on the ampliﬁability
of plasma cfRNA using RT-qPCR of β-actin and c-fos as targets and
found no statistically signiﬁcant decrease in treated plasma compared
to untreated plasma (Fig. 2B and C). Holford et al. [14] however,
studied the stability of plasma β-actin mRNA in blood stored at 4 °C
over 5 h and had shown a rapid decrease in β-actin mRNA concentra-
tion within the ﬁrst hour post phlebotomy. After this initial change,
β-actin mRNA was then relatively stable for up to 5 h. This rapid
change is not reﬂected in our β-actin measurements, which we suggest
may be due to the clearance of the non-particle associated cfRNA by theaction of plasma RNases. In our experiments described in Fig. 2, 1 to 2 h
elapsed during the preparation of untreated and treated plasmas. Any
processing delay may allow the degradation of non-particle associated
cfRNA in our samples by plasmaRNases, leaving only particle associated
RNase resistant cfRNA. This may explain the discrepancy between our
results and the results published by Holford et al.
Comparison of c-fos mRNA concentrations in untreated and
chemically treated groups also shows that the chemical cocktail had
no adverse effect on the ampliﬁability of RNA (Fig. 2C). The treated
group had higher mRNA copy numbers as compared to the untreated
group at all time points. However, the stability of proto-oncogene c-fos
mRNA in plasma at room temperature differed from the housekeeping
gene β-actin mRNA. There was a signiﬁcant decrease in c-fos mRNA
concentration in the untreated group over time. We speculate that
this difference may be due to the inherent instability of c-fos mRNA
at room temperature. In the chemically treated group, c-fos mRNA
was relatively stable compared to the untreated group and showed
decreases on days 2 and 3 (0.7-fold and 0.6-fold, respectively). We
suggest that the improved stability compared to untreated plasma is
conferred by the BCT chemical cocktail.
Salway et al. [15] found that plasma GAPDH mRNA concentrations
increase with time in whole blood samples. Our experiments on
blood cell stability have shown that erythrocytes are stable in K3EDTA
and BCT during 3 days of incubation at room temperature while
white blood cells were stable only in BCT. In the K3EDTA collection
device, white blood cells degrade markedly after 24 h of storage at
room temperature. Therefore, we suggest that the increase in GAPDH
mRNA concentration observed by Salway et al. is caused by the release
of bRNA during cell degradation, most likely that of white blood cells.
In our RT-qPCR experiments of GAPDH, c-fos, and 18S cfRNA, ex vivo
room temperature storage of blood samples drawn into K3EDTA
tubes resulted in statistically signiﬁcant increases in mRNA concentra-
tion. Detection of the same genes did not signiﬁcantly change in plasma
isolated from whole blood that had been stabilized in BCTs except
for GAPDH on day 3, which showed a minor 1.5-fold increase. This
suggests that the cocktail present in the new blood collection device
minimized non-speciﬁc bRNA release into plasma during sample pro-
cessing and storage, which could have masked the presence of cfRNA
and limit its use as a biomarker.
In order to minimize cfRNA degradation and prevent increases in
bRNA, present protocols dictate that whole blood should be centrifuged
immediately post-phlebotomy and the plasma processed. However, in
situations where testing is performed at a location other than the blood
draw site, this procedure becomes even more challenging due to the
requirement for cryopreservation after plasma separation. This necessi-
tates that phlebotomy sites have the equipment for centrifugation and
cryopreservation as well as a trained staff. Use of the new device could
overcome these burdens, since the novel chemical cocktail signiﬁcantly
inhibits plasma RNase activity and prevents the non-speciﬁc release of
bRNA. Storage of cfRNA samples in the original draw tube at room
temperature for up to 3 days is now a viable option. This stabilization
technology would permit smaller labs to collect multiple samples for
optimized single processing events or allow for transfer of stabilized
samples to a more competent or better equipped core-like facility.
The BCT could provide convenience for shipment to a centralized
facility for sample processing and analysis. All of these situations
require the additional ﬂexibility and utility in cfRNA analysis that
would be provided by the novel device, in research and clinical
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